Sector News

Shareholder group critical as Roche and Novartis chiefs top Swiss pay table

October 9, 2014
Life sciences
(Reuters) – The bosses of drugmakers Roche and Novartis both earned more than 13 million Swiss francs ($13.6 million) last year, according to a study published on Wednesday, 18 months after the Swiss voted for some of the world’s strictest controls on executive pay.
 
The pay packets of Roche CEO Severin Schwan and Novartis counterpart Joe Jimenez topped the list of Switzerland’s best-paid managers and prompted criticism from shareholder group Ethos, which conducted the study.
 
“Double-digit sums are difficult to accept in Switzerland,” Ethos director Dominique Biedermann told reporters. “When Mr Schwan and Mr Jimenez earn 13 million in a good year, but not a record year, what will they earn in a record year?”
 
Last year Swiss voters backed proposals to give shareholders the power to veto executive pay proposals as well as banning big rewards for new and departing managers. Companies have until the end of 2015 to implement the measures.
 
Ethos said the initiative appeared to have slowed the growth in executive pay, with overall compensation staying broadly stable despite a sharp rise in company share prices and profit.
 
Roche’s Schwan earned 13.4 million francs, a drop of 13 percent from the previous year, while Jimenez’s Novartis remuneration was stable at 13.2 million francs.
 
Executive pay at Switzerland’s 100 biggest companies rose 2 percent last year, driven by an 8 percent rise in salaries in the financial services sector. Pay in other industries slipped by 1 percent.
 
Average CEO pay in Switzerland rose 4 percent to 3.4 million francs, while that of a non-executive chairman fell 7 percent to 1.2 million francs.
 
(Reporting by Caroline Copley; Editing by David Goodman)

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach